Anxiety disorders are among the most prevalent mental health conditions worldwide and are commonly understood within biomedical frameworks as arising from complex interactions of genetic, neurobiological, psychosocial and environmental factors. Although existing treatments, including pharmacotherapy and psychotherapy, can alleviate symptoms, they often fail to provide definitive or preventive solutions for all patients. The persistence of unexplained symptoms and treatment-resistant cases suggests that additional underlying mechanisms may exist beyond current scientific models. Therefore, this study explores a Dharma-based perspective, as articulated in the Guan Yin Citta Dharma Door, which attributes anxiety disorders to karmic and spiritual causes. Through analysis of practitioner-reported cases and question-and-answer records, this study examines the potential therapeutic effects of practices such as vow-making, Buddhist Scripture recitation, and life release. The findings indicate a consistent pattern of perceived symptom alleviation and recovery following sustained engagement in these practices. These results suggest that Dharma-based interventions may offer a complementary, holistic approach to understanding and managing anxiety disorders, warranting further systematic investigation.

N/A

Background: Depression is one of the most common psychiatric disorders observed among patients suffering from chronic medical illnesses. The coexistence of depression with chronic diseases such as diabetes, hypertension, chronic kidney disease, and chronic obstructive pulmonary disease can significantly worsen clinical outcomes, reduce treatment adherence, and impair quality of life. Early detection and management of depression in such patients are therefore essential. Aim and Objectives: To determine the prevalence of depression among patients with chronic medical illnesses and to evaluate its association with various demographic and clinical factors. Materials and Methods: This hospital-based observational cross-sectional study was conducted in the Department of Psychiatry, Geetanjali Institute of Medical Sciences, Jaipur, over a period of 6 months. A total of 50 patients with chronic medical illnesses were included in the study. Socio-demographic and clinical data were collected using a structured proforma, and depression was assessed using a standardized depression screening scale. Statistical analysis was performed to determine the association between depression and different variables. Results: The prevalence of depression among patients with chronic medical illness was 42%. Depression was more common among female patients and those with longer duration of illness (≥5 years), showing statistically significant associations. Variables such as age group, socioeconomic status, marital status, and type of chronic illness did not show statistically significant associations with depression. Conclusion: Depression is highly prevalent among patients with chronic medical illnesses and is influenced by several demographic and clinical factors. Routine screening and early psychiatric intervention are essential for improving treatment outcomes and overall quality of life.

A/F

A/F

Background: Omega-3 polyunsaturated fatty acids (n-3 PUFAs) are essential for brain function and have been increasingly studied for their potential preventive and therapeutic roles in depression. Methods: A systematic review was conducted in accordance with PRISMA guidelines, focusing on recent human studies evaluating the effects of n-3 PUFA supplementation and Mediterranean dietary patterns on depression-related outcomes. Studies were identified through electronic databases and manual searches and critically appraised using the Joanna Briggs Institute Checklist for Randomized Controlled Trials. To contextualize human data, relevant preclinical animal studies were also reviewed. Results: The review identified mixed and context-dependent evidence for the efficacy of n-3 PUFAs in depression prevention among general populations. In contrast, more consistent therapeutic effects were observed in treatment studies, particularly when EPA-predominant formulations were used as adjunctive interventions. However, many studies lacked statistical power or did not achieve significance. Six preclinical studies demonstrated robust antidepressant and anxiolytic effects of EPA and DHA across models of nicotine withdrawal, chronic stress, aging, and neurotrophin deficiency. These effects were linked to anti-inflammatory, neuroprotective, and neurotrophic mechanisms. Conclusions: Omega-3 PUFAs—especially EPA—may offer modest yet clinically relevant benefits as adjunctive treatments for depression. While preventive efficacy remains unclear, preclinical data provide strong mechanistic support. Future large-scale, biomarker-informed human trials are warranted to clarify efficacy and optimize dosing strategies

Chronic subdural hematoma (CSDH) is a frequent neurosurgical issue, but ischemic cerebrovascular accidents (CVA) following surgery for CSDH are rare and present significant clinical challenges, especially in patients requiring oral anticoagulation (OAC). This case describes an 87-year-old male with atrial fibrillation who developed acute right-sided weakness and aphasia due to an M2 segment occlusion of the left middle cerebral artery (MCA), two weeks after bilateral CSDH evacuation and OAC cessation (the "Apixaban Gap"). The patient underwent successful mechanical thrombectomy with TICI 3 reperfusion, demonstrating marked clinical improvement and favourable functional recovery within three months. This case underscores the risks associated with perioperative anticoagulant interruption in high-risk patients and highlights the therapeutic dilemma in managing concurrent hemorrhagic and thrombotic complications. The technical feasibility and benefit of mechanical thrombectomy for medium vessel occlusions (MeVO) in the post-neurosurgical context are discussed. Ultimately, the case supports individualized, multidisciplinary decisions for early intervention and timely re-initiation of OAC, showing that neither advanced age nor recent neurosurgical history should be absolute contraindications to life-saving stroke interventions when stringent selection and rapid workflows are maintained.